About this trial
This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.
Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes.
The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.
Eligibility criteria
Qualifiers
Age 18 years or older.
Followed in the critical care area of the Emergency Department of Antalya
Training and Research Hospital between January 1, 2023, and August 1, 2026.
Presence of an indication for emergency renal replacement therapy.
Disqualifiers
Age younger than 18 years.
Renal replacement therapy initiated outside the emergency department.
Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.
Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.
Trial design
Treatments tested in this trial
- Hemodialysis (HD)
- Continuous Venovenous Hemodiafiltration (CVVHDF)